Teachers Advisors LLC Has $686,000 Stake in Cempra, Inc. (CEMP)
Teachers Advisors LLC grew its stake in Cempra, Inc. (NASDAQ:CEMP) by 23.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,128 shares of the biotechnology company’s stock after acquiring an additional 28,460 shares during the period. Teachers Advisors LLC owned 0.28% of Cempra worth $686,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Janney Montgomery Scott LLC grew its holdings in shares of Cempra by 35.6% in the 2nd quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 6,800 shares in the last quarter. UBS Asset Management Americas Inc. bought a new position in Cempra during the first quarter worth about $140,000. LMR Partners LLP bought a new position in Cempra during the second quarter worth about $149,000. State of Wisconsin Investment Board bought a new position in Cempra during the second quarter worth about $166,000. Finally, Rhumbline Advisers grew its holdings in Cempra by 13.8% during the second quarter. Rhumbline Advisers now owns 65,586 shares of the biotechnology company’s stock worth $302,000 after purchasing an additional 7,928 shares during the period. Institutional investors own 49.36% of the company’s stock.
CEMP has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Cempra from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. Jefferies Group LLC reiterated a “hold” rating and set a $3.00 price target on shares of Cempra in a report on Thursday, September 14th. Roth Capital cut Cempra from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $8.00 to $4.00 in a report on Thursday, August 10th. Stifel Nicolaus reiterated a “hold” rating and set a $4.00 price target on shares of Cempra in a report on Thursday, August 10th. Finally, Robert W. Baird upgraded Cempra from an “underperform” rating to a “neutral” rating and set a $2.00 price target for the company in a report on Wednesday, November 1st. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $7.83.
Shares of Cempra, Inc. (CEMP) opened at $2.33 on Wednesday. The company has a current ratio of 11.49, a quick ratio of 11.49 and a debt-to-equity ratio of 0.03. Cempra, Inc. has a 1 year low of $10.25 and a 1 year high of $47.00.
Cempra (NASDAQ:CEMP) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. Cempra had a negative net margin of 500.05% and a negative return on equity of 45.72%. The company had revenue of $0.86 million during the quarter, compared to the consensus estimate of $3.58 million. During the same period in the previous year, the business earned ($0.51) earnings per share. The firm’s quarterly revenue was down 74.9% on a year-over-year basis. equities analysts expect that Cempra, Inc. will post -1.01 EPS for the current fiscal year.
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Stock Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related stocks with our FREE daily email newsletter.